APT is featured in episode 2 of the Netflix series Connected. Science journalist Latif Nasser investigates the surprising and intricate ways in which we are connected to each other, the world and the universe.
For scientists, clinical trials like these are a first try. For participants, they are often a last hope. At the brink of giving up, John Haverty turned to internet research. He was aware of phage treatment [the therapeutic use of bacteriophages to treat bacterial infections like Haverty’s], and he happened across Maryland-based Adaptive Phage Therapeutics.
GAITHERSBURG, Md.–Mayo Clinic and Adaptive Phage Therapeutics (APT) today announced a collaboration to advance and commercialize a phage susceptibility test (PST) linked exclusively to APT’s phage bank investigational therapy. At launch, the PST will be offered as a laboratory developed test for worldwide commercial availability by Mayo Clinic Laboratories (MCL). The PST will enable rapid […]
By learning from the past, we may have a much better arsenal against antimicrobial-resistant bacteria in the near future.
Adaptive Phage Therapeutics was featured in an April 28 broadcast in the Netherlands, Dokters van morgen, discussing the treatment of stubborn infections. The discussion regarding APT begins at the 35 minute mark and features John Haverty (a patient helped by APT).
“Never Give Up on Your Life” – John Haverty. John Haverty is a chef, a family man, a patient who was battling a stubborn bacterial infection in his leg for over 10 years. He wasn’t able to walk and put both feet on the ground for over 10 year. Doctors at Mayo Clinic were about […]
GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the clinical development of APT’s phage bank™, a personalized bacteriophage therapeutic for […]
February 13, 2020 | To fully appreciate the potential of Adaptive Phage Therapeutics (APT), it’s helpful to review history through the lens of company co-founder and Chief Scientific Officer Carl Merril. For nearly five decades, Carl has been championing the idea of using bacteriophages to treat infectious diseases—an idea for which he has been variably applauded, questioned, ignored, scolded, and, ultimately, vindicated.
Bacteriophage: A Force Of Nature As bacteria evolve to become more resistant to antibiotics, dangerous infections are taking their toll on human lives. We hear from John Haverty who, after knee replacement surgery generated an unrelenting infection … found himself facing amputation of his leg. Enter a new treatment called ‘phage therapy’ and Greg Merril, […]
Company is Recognized Top 1% among 4,000 applicants from 133 Countries GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that the company has been selected to participate in the Accelerate Program at the Startup […]